Sohi Mohsen sold $957K of STE

Sohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.

Original reporting
SEC EDGAR · Sohi Mohsen
Published Aug 12, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by a director on 2026-08-12.

02

Market read

A director’s open-market sale is disclosed, but there is no accompanying operational, financial, or regulatory catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, trading impact is usually limited.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 (same day as transaction)

Background

The article is an SEC Form 4 insider transaction disclosure for STERIS plc.

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

STERIS director Sohi Mohsen filed a Form 4 selling 4,058 shares at $235.7800 on 2026-08-12 for about $956,795.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no accompanying company news, guidance, or transaction context beyond the sale details.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

Absence of a disclosed 10b5-1 plan could be interpreted as less mechanical selling, but the article still lacks any linkage to company fundamentals.

Key entities

  • STERIS plc

    Subject of the Form 4 insider transaction disclosure.

  • Sohi Mohsen

    Director who sold 4,058 shares on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STEMedAI 8/10

STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland and a wholly-owned subsidiary of STERIS plc, a public…

STERIS plc (STE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 9, 2026, STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland (the “Issuer”) and a wholly-owned subsidiary of STERIS plc, a public limited company incorporated under the laws of Ireland (the “C

$STEMed

What STERIS (STE) Said on Its Q2 Earnings Call

STERIS (STE) reported Q2 adjusted EBIT margin up 150 bps to 24.6%, with EPS growth of 13% excluding refunds. Life Sciences revenue rose 18%, leading to an increased full-year growth forecast of 9-10%. AST segment revenue grew 5%, but its forecast was lowered to 6-7%. The company announced a $45M restructuring plan and expects its Xodus Medical acquisition to boost revenue and margins.

$STEMed

Steris PLC (STE) (Q2 2027) Earnings Call Highlights: Revenue Climbs 9%

STERIS PLC reported Q2 2027 revenue up 9%, but EBIT margins declined in both Healthcare and AST segments due to inflation and other factors. AST revenue growth guidance was lowered. Free cash flow decreased. A $45M restructuring plan was announced. CEO Dan Carestio discussed growth opportunities, including the Xodus Medical acquisition, and addressed margin pressures and market dynamics.

$STEHighAI 8/10

STERIS (STE) Q2 2027 Earnings Call Transcript

STERIS (STE) reported Q2 2027 earnings with adjusted EBIT margin at 24.6%, up 150 bps YoY. Adjusted EPS grew 19% to $2.94. Revenue grew 7-8%, with Healthcare up 7%, AST up 5%, and Life Sciences up 18%. The company announced plans to acquire Xodus Medical. Full-year EPS outlook raised to $11.35-$11.55. Free cash flow was $492.5M for H1 2027.

$CATMedAI 8/10

Caterpillar's $1B Sanford Plant Fuels Raleigh-Durham Growth

Caterpillar plans to invest $1B in a North Carolina plant, expanding manufacturing capacity. The project is part of a broader industrial surge in Raleigh-Durham, with increased leasing activity and construction. Other companies, including AbbVie, Siemens, and Forge Nano, are also investing in the region. Research Triangle Park is diversifying with mixed-use and residential developments.